View in EDS HTML Full Text PDF Full Text

Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials.

Saved in:
Bibliographic Details
Title: Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials.
Authors: Burmester, Gerd R.1 (AUTHOR) gerd.burmester@charite.de, Winthrop, Kevin2 (AUTHOR), Blanco, Ricardo3 (AUTHOR), Nash, Peter4 (AUTHOR), Goupille, Philippe5 (AUTHOR), Azevedo, Valderilio F.6 (AUTHOR), Salvarani, Carlo7 (AUTHOR), Rubbert-Roth, Andrea8 (AUTHOR), Lesser, Elizabeth9 (AUTHOR), Lippe, Ralph10 (AUTHOR), Lertratanakul, Apinya9 (AUTHOR), Mccaskill, Reva M.9 (AUTHOR), Liu, John9 (AUTHOR), Ruderman, Eric M.11 (AUTHOR)
Source: Rheumatology & Therapy. Apr2022, Vol. 9 Issue 2, p521-539. 19p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:21986576
DOI:10.1007/s40744-021-00410-z